Salt Lake City-based Myriad Genetics and Intermountain Precision Genomics, St. George, Utah, have formed a new strategic collaboration. The companies are creating a comprehensive germline genetic testing and somatic tumor offering that combines Myriad’s advanced hereditary cancer and companion diagnostic tests with Intermountain Precision Genomics’ world-class laboratory services, utilizing the TheraMap test—powered by the TruSight Oncology 500 (TSO 500) next-generation sequencing test from Illumina, San Diego.
TSO 500 is rapidly becoming a standard in oncology. Through the offering, oncologists will obtain a complete genetic analysis in one, easy-to-interpret report, enabling them to leverage the benefits of comprehensive genomic profiling.
“As cancer treatment continues to evolve, most oncologists seek both germline and somatic tumor testing results to best guide treatment decisions. Advancing precision oncology requires strong collaboration between forward-looking organizations across the healthcare ecosystem. This alliance with Intermountain Precision Genomics is an example of our drive to improve health outcomes for patients with cancer and expand innovative treatment options for the healthcare providers who care for them,” says Paul J. Diaz, president and CEO, Myriad Genetics. “We are successfully merging the power of companion diagnostics, next-generation tumor sequencing, and world-class testing services to help raise the global standard of care in precision oncology.”
“As a physician, I’m excited to make this comprehensive offering available to more patients,” says Lincoln Nadauld, MD, PhD, oncologist and vice president and chief of precision health and academics at Intermountain Healthcare. “This partnership allows us to make a tremendous impact by providing the best that precision cancer care has to offer.”